Rating Change
Brookline Capital analysts initiated coverage on Biomea Fusion, Inc. (NASDAQ:BMEA) with a rating of Buy on October 07, 2026.
new coverageNASDAQ:BMEA
Brookline Capital Initiates Coverage on Biomea Fusion, Inc. (BMEA) with Buy
Brookline Capital analysts initiated coverage on Biomea Fusion, Inc. (NASDAQ:BMEA) with a rating of Buy on October 07, 2026.
At publication ·
What changed
Biomea Fusion, Inc. (NASDAQ:BMEA) · new coverage
- Firm
- Brookline Capital
- Rating
- Buy
- Price at event
- $1.32
- Market capitalization
- $90.4M
At a glance
Key takeaways
- Brookline Capital initiated Buy coverage on Biomea Fusion (BMEA) on October 7, 2026, as the stock trades at $1.32 with a $90.4M market capitalization.
Market Context
Biomea Fusion, Inc. operates in the Healthcare sector. The stock currently trades at $1.32 with a market capitalization of $90.4M.
Analyst coverage from Brookline Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biomea Fusion, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Biomea Fusion, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Brookline Capital | Buy | N/A |
| May 05, 2026 | Citizens | Market Outperform | N/A |
| Apr 28, 2026 | D. Boral Capital | Buy | N/A |
| Apr 08, 2026 | D. Boral Capital | Buy | N/A |
| Mar 27, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BMEA Stock Page
Frequently Asked Questions
What does the Buy rating mean for BMEA?
A rating of Buy from Brookline Capital reflects the analyst's outlook on Biomea Fusion, Inc. (NASDAQ:BMEA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BMEA forecast page.
